Brief: PureTech Health Expects Topline Data For Phase 3 Restorative303 Study In 2026

Puretech Health

27/01/2025 07:25

Jan 27 (Reuters) - PureTech Health PLC  PRTC.L :
    * PURETECH HEALTH PLC - VE303 WELL TOLERATED, DECREASED ODDS
OF
RCDI
    * PURETECH HEALTH PLC - TOPLINE DATA FOR PHASE 3
RESTORATIVE303
STUDY EXPECTED IN 2026

Source text:  ID:nBw2pYVYca 
Further company coverage:  PRTC.L 

 ((Reuters.Briefs@thomsonreuters.com))